SCHEMBL30867813

SCHEMBL30867813

CC(C)(C)OC(=O)N1CCN(c2c(Cl)cnn2C2COC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 1/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NPBWR1 P48145 1/20 0.43
▸ MCHR1 Q99705 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ NR3C1 P04150 2/20 0.42
▸ ALK Q9UM73 2/20 0.42
▸ CKS1B P61024 1/20 0.42
▸ SKP1 P63208 1/20 0.42
▸ SKP2 Q13309 1/20 0.42
▸ GPR119 Q8TDV5 4/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ PIK3CG P48736 1/20 0.41
▸ ATR Q13535 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38654099 0.86 GPR119 (0.46) MAPTNPBWR1MCHR1GPR119PIK3CA
SCHEMBL38653471 0.81 MEN1 (0.52) MAPTMEN1KMT2ASMN1; SMN2NPBWR1
SCHEMBL38653656 0.78 GPR119 (0.44) MAPTSMN1; SMN2POLBCKS1BSKP1
SCHEMBL38654315 0.78 NPBWR1 (0.42) MAPTMEN1KMT2ANPBWR1MCHR1
SCHEMBL30867765 0.76 GPR119 (0.51) MAPTGPR119PIK3CA
SCHEMBL30911167 0.76 GPR119 (0.46) GPR119PIK3CA
SCHEMBL30911135 0.76 GPR119 (0.46) GPR119PIK3CA
SCHEMBL30911096 0.75 SMARCA2 (0.48) GPR119PIK3CAMTORPIK3CGATR
SCHEMBL30872476 0.73 POLB (0.48) MAPTMEN1KMT2APOLB
SCHEMBL22504048 0.72 NR1H2 (0.40) MAPTSMN1; SMN2GPR119PIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 — — US disclosed
EP-4598917-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 — — EP disclosed
WO-2024076674-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS RET 226/4885MAPT 4771/4885MEN1 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback